MBVX News Alert Mabvax Therapeutics Holdings Inc. (MBVX) 1.9700

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mabvax Therapeutics Holdings Inc. (MBVX) 1.9700 $MBVX

Missed the Juno IPO? Take a Look at MabVax
ACCESSWIRE - Mon Dec 22, 8:33AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2014 / When an initial public offering soars over 50% right out of the gate, you almost never get a second chance to buy at the IPO price. Juno Therapeutics (NASDAQ:JUNO), an oncology-focused biotech not even a year and a half old, accomplished just that on Friday when it offered shares at $24 a piece and closed its first trading day just below $37.
JUNO: 39.99 (+2.71), NVS: 93.91 (+0.66)

MabVax Therapeutics Selected To Make Corporate Presentation at January 2015 BIOTECH Showcase
PR Newswire - Thu Dec 11, 7:30AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a cancer diagnostic and immunotherapy company, announced today that it has been selected to make a corporate presentation in the public company program at the upcoming BIOTECH Showcase event. The company is scheduled to present at 9:00 am on Wednesday, January 14th in the Powell presentation room at the Parc 55 Wyndham Hotel in San Francisco. MabVax will present a corporate update including highlighting the significant progress made in the last year on the development of its lead antibody candidate HuMab 5B1 as a diagnostic product and therapeutic agent in the diagnosis and treatment of GI cancers and specifically pancreatic cancer. MabVax's CEO David Hansen will also update investors and interested corporate entities on the therapeutic cancer vaccine program, which has two products in late stage Phase II clinical trials. He will also discuss the upcoming Phase II trial in the childhood cancer neuroblastoma for which MabVax received an Orphan Drug Designation from FDA in September of this year.

Delisting of Securities of GT Advanced Technologies, Inc., Dendreon Corporation, MabVax Therapeutics Holdings, Inc., and Tri-Tech Holding Inc. From The Nasdaq Stock Market
GlobeNewswire - Wed Dec 10, 3:05PM CST
The Nasdaq Stock Market announced today that it will delist the common stock of GT Advanced Technologies, Inc. GT Advanced Technologies, Inc.'s stock was suspended on October 16, 2014 and has not traded on Nasdaq since that time.
NDAQ: 48.74 (-0.40)

MabVax At The Intersection Of Vaccine And Antibody Cancer Immunotherapy
Austrolib - at Seeking Alpha - Tue Dec 09, 8:14AM CST


A New Combined Approach to Cancer Immunotherapy is Needed
ACCESSWIRE - Mon Dec 01, 11:35AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2014 / With the recent bankruptcy of Dendreon Corporation (NASDAQ NDN) due to disappointing sales of its flagship Provenge prostate cancer vaccine, the future of cancer immunotherapy just got a bit cloudier. While Provenge itself will survive, Dendreon may end up going private in a debt restructuring deal.
DNDN: 0.13 (-0.02), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01)

MabVax Therapeutics And Memorial Sloan-Kettering Cancer Center Report on Potential Use of Dual-Labeled Antibody To Detect and Guide Surgical Removal of Pancreatic Cancer
PR Newswire - Wed Nov 19, 1:00PM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical stage oncology drug development company in conjunction with the Department of Radiology at Memorial Sloan-Kettering Cancer Center (MSKCC) presented results on the use of MabVax's lead antibody development candidate, HuMab 5B1, as the targeting vehicle carrying two different imaging agents intended to significantly improve the imaging of pancreatic tumors and facilitate more effective cancer resections. The results were presented at the World Molecular Imaging Congress in Seoul, South Korea by Jacob Houghton, Ph.D. and Jason Lewis, Ph.D. of MSKCC. The HuMab 5B1 antibody was conjugated individually to a near-infrared fluorescent agent (NIRF) for optical imaging and desferrioxamine (DFO), a chelate used to radiolabel with Zirconium-89 (89Zr) for PET imaging. Each singly labeled construct performed well in illuminating the targeted tumors. Additionally, a dual-labeled construct was prepared to incorporate the advantages of both modalities into a single construct. The dual-labeled HuMab 5B1 yielded high-resolution PET images of the targeted cancer and its metastases prior to resection while the fluorescent label significantly enhanced the imaging of the tumor and definition of tumor margins during resection in multiple murine models of pancreatic cancer. The imaging agent developed in this study showed exceptional potential as a tool to aid in the diagnosis, staging, and resection of pancreatic cancer.

MabVax Is Under The Radar, But Undervalued: CEO David Hansen
Trevor Lowenthal - at Seeking Alpha - Mon Nov 17, 10:22AM CST


MabVax Therapeutics - "Introducing MabVax Therapeutics: Newly Public Company Achieves Multiple Milestones in Recent Quarter"
ACCESSWIRE - Thu Oct 23, 7:16AM CDT
New York, NY / ACCESSWIRE / October 23, 2014 / MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, David Hansen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

MabVax Therapeutics Launches Online Corporate Communication Channels and New Website
PR Newswire - Thu Oct 23, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter, LinkedIn, Google+, and The Chairman's Blog.

MabVax Therapeutics Nominates The Fully Human Antibody HuMab 5B1 As The Company's Lead Clinical Development Candidate
PR Newswire - Tue Oct 21, 8:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical stage oncology drug development company, announced today that it has formally nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer. The fully human antibody, recovered from patients undergoing cancer vaccine treatment at Memorial Sloan-Kettering Cancer Center, has entered GMP manufacturing to produce clinical trial supplies for a planned Phase 1 program to begin in the second half of 2015. The development plan calls for dual Phase 1 clinical trials to take place simultaneously. One program will be aimed at demonstrating the utility of the radio-labeled antibody as a novel PET imaging agent for the diagnosis and management of pancreatic cancer. The second program will determine the safety and potential utility of the full-length antibody as a treatment for the same cancer.

MabVax Therapeutics reports change in common stock ticker symbol
M2 - Mon Oct 13, 8:30AM CDT
Oncology company MabVax Therapeutics Holdings said on Friday that its common shares will commence trading under the new trading symbol MBVX (OTCQB:MBVX.).




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 41

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 97

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 94

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 137

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 111

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 111

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 104

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 71

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Mission Rock Takes Charge of Seasons at Horsetooth

Updated Category News Views 20

Mission Rock Shakes Up Colorado's Apartment Market Here's one for the books: Mission Rock Residential, known for its no-nonsense approach to property management, just snagged a juicy piece of the market by taking over management at Seasons at Horsetooth Crossing in Fort Collins. Fort Collins isn't just some random name on the map—it's a hotbed for real estate, thanks to...

Continue Reading
Teck Resources Confirms Quarterly Dividend for Shareholders

Updated Category News Views 175

Teck Resources Declares New Dividend for Shareholders Teck Resources Limited (NYSE: TECK) has made an exciting announcement that will please its investors. The company has declared a quarterly dividend of $0.125 per share designated for its outstanding Class A common shares and Class B subordinate voting shares. This dividend is set to be paid on March 31 to all...

Continue Reading
Empowering Voices: The Impact of the AWDPI Conference

Updated Category News Views 300

Empowering Women Through Innovative Discussions The recent conference organized by the Asian Women Development Plan International brought together over 10,000 individuals passionate about empowering Asian women. This pivotal gathering, titled "The Conference of Asian Women Development International 2024", served as a beacon for women's issues, fostering a collaborative...

Continue Reading
O2Gold Shares Significant Updates on Quebec Aur Acquisition

Updated Category News Views 205

O2Gold's Exciting Update on Quebec Aur Acquisition O2Gold Inc. (NEX:OTGO.H), a dynamic player in the mineral exploration landscape, is thrilled to provide an update on its ongoing journey towards acquiring a gold mining exploration property in Quebec. This acquisition is through the purchase of Quebec Aur Ltd., with the transaction details specified in a share exchange...

Continue Reading
Skycorp Solar Group Limited Announces Major IPO Initiative

Updated Category News Views 187

Skycorp Solar Group Limited Announces Major IPO Initiative Skycorp Solar Group Limited (PN) has made a notable move by filing for an initial public offering (IPO) that encompasses 2,000,000 shares. The pricing is positioned attractively between $4 and $5 per share, appealing to a diverse range of potential investors. Understanding the IPO Process An IPO is a crucial step...

Continue Reading